case_images: PMC11295210_01
case_images: (A) The sequence of immunosuppressant administration and process of prednisone reduction. (B) Chest HRCT before and after (i) baseline pulmonary condition; (ii) acute relapse with RP-ILD, HRCT shows bilateral ground-glass opacities, diffuse exudation, and consolidation; (iii) 1 month after relapse with RP-ILD; (iv) 1 year after relapse with RP-ILD, HRCT shows significant improvement in the pulmonary after 1 year of TCZ treatment.. MMF, mycophenolate morphenate; CsA, cyclosporine; MTX, methotrexate; TOF, tofacitinib; RTX, rituximab; TCZ, tocilizumab.
case_images: 10.1177_23247096241267153-fig1.jpg
case_images: PMC11295210_01_10.1177_23247096241267153-fig1.jpg
case_images: fig1-23247096241267153
case_images: Given the ongoing acute exacerbation of ILD and hyperinflammatory status, we initiated the treatment with intravenous methylprednisolone at 160 mg/d for 3 days and intravenous TCZ, which was given at a dose of 480 mg, followed by 320 mg 2 weeks later, and then administered at 400 mg (8 mg/kg) every 4 weeks for 9 months (Figure 1A).